Streptococcus Pneumoniae Clinical Trial
Official title:
PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study
Objective: PCV effects on S. pneumoniae and S. aureus carriage in a population based study.
The major specific aims:
1. To compare different PCV vaccination policies, by cross-sectional repeated surveillance
of closely related populations living in regions with different vaccination policies.
2. To compare the epidemiology, predictors and outcomes of antibiotic resistant S. aureus
and S. pneumoniae in different regions of the PICR.
Study design: Annual / Biannual cross-sectional surveillance of nasal S. aureus carriage and
nasopharyngeal S. pneumoniae carriage in children and one of their parents.
Study design: Annual / Biannual cross-sectional surveillance of nasal S. aureus carriage and
nasopharyngeal S. pneumoniae carriage in children and one of their parents.
PICR districts: 1. Palestinian Authority (PA) - particularly: Bethlehem, Ramallah and
Nabulus. 2. East Jerusalem (EJ) 3. Central Israel (IL) - particularly: Rishon Lezion, Bat
Yam, Holon 4. Gaza strip (GZ) - 12 regions including cities/villages in central/northern
Gaza.
Study population:
Child (age 0-5y) & Parent who attend clinics (for any reason).
Exclusion criteria:
Parent does not agree to sign informed consent Child or sibling (brother/sister) have
already participated.
Both healthy and ill children are screened. No specific exclusion other than the above.
Only one child per family (younger child, if more than one available) and one parent
(mother, if both are available).
Sample size per year:
IL: Central Israel (Hashfela District): 400 pairs of child+parent/surveillance EJ: East
Jerusalem: 400 pairs of child+parent/surveillance PA: West Bank cities (Ramallah, Bethlehem
& Nabulus): 600 pairs of child+parent/surveillance GZ: Gaza strip: 300 pairs of
child+parent/surveillance
Study Period:
May-August annually 2009 - 2011 - (Part a). May-August biannually 2014-2016-2018-2020
Current study (Part b).
Screening Procedure:
1. Parent signs informed consent
2. Put Barcode stickers on informed consent, questionnaire, swabs and daily list
3. Fill questionnaire with parent.
4. Fill physician questionnaire
5. Nasal & nasopharyngeal swab of child and parent.
6. Fill daily working table.
7. Write the number of refusals (parents who refused) on daily table.
8. Fill questionnaire FULLY (unmarked questions will not be analyzed) - put x on each
question - whether YES or NO.
Swabbing:
1. First swab the child and then follow with the parent.
2. First perform nasal swab (for S. aureus) using cotton-tip swab placed into Amies
transport Media (Blue) and follow with nasopharyngeal swab ( for S. pneumoniae) using
rayon-tipped aluminum shaft swab placed in Amies transport Media (Orange).
3. Slightly wet the nasal swab with sterile saline. Swab both anterior nares.
4. Nasopharyngeal swab of only through one nostril - gently, quickly and deep to
nasopharynx - until you touch the nasopharyngeal wall.
Swab transfer to lab:
If swabs are stored overnight before transfer - keep in 40C (fridge). Within 24h swabs must
reach the central laboratory (Dr. Regev-Yochay's Lab at Sheba Medical Center).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT02215863 -
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
|
Phase 4 | |
| Completed |
NCT01521897 -
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
|
N/A | |
| Completed |
NCT00197769 -
Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants
|
Phase 2 | |
| Completed |
NCT02888457 -
Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Centers
|
N/A | |
| Completed |
NCT01995617 -
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
|
Phase 1 | |
| Completed |
NCT01425372 -
Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
|
||
| Completed |
NCT00594347 -
Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar
|
Phase 3 | |
| Completed |
NCT00861380 -
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
|
Phase 3 | |
| Active, not recruiting |
NCT00900978 -
Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT00814710 -
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age
|
Phase 3 | |
| Suspended |
NCT01308827 -
Costa Rica Epidemiological Study on S. Pneumoniae
|
N/A | |
| Recruiting |
NCT04078997 -
An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
|
||
| Terminated |
NCT00849069 -
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
|
Phase 1 | |
| Recruiting |
NCT06096025 -
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
|
||
| Completed |
NCT00907777 -
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
|
Phase 3 | |
| Completed |
NCT00273325 -
Immunogenicity of PCV-7 Vaccine in VLBW Infants
|
||
| Completed |
NCT00814489 -
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
|
Phase 1 | |
| Completed |
NCT01730391 -
Neisseria Meningitidis Burden of Disease Study
|
N/A | |
| Completed |
NCT00197821 -
Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults
|
Phase 2 |